Tumour heterogeneity: The key advantages of single-cell analysis

International Journal of Molecular Sciences

Volumn 17, Issue 12, 2016, Pages

  Tellez Gabriel, Marta ^a   Ory, Benjamin ^b   Lamoureux, Francois ^b   Heymann, Marie Francoise ^b,c,d   Heymann, Dominique ^b,c,d  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITÉ DE NANTES   (France)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Circulating tumour cells; Heterogeneity; Single cells

Indexed keywords

CELL HETEROGENEITY; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CIRCULATING TUMOR CELL; COMPARATIVE GENOMIC HYBRIDIZATION; DNA RNA HYBRIDIZATION; EPIGENETICS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METASTASIS POTENTIAL; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROTEOMICS; REVIEW; SINGLE CELL ANALYSIS; TRANSCRIPTOMICS; GENETICS; METASTASIS; NEOPLASM; PATHOLOGY; PHENOTYPE; PROCEDURES; TUMOR EMBOLISM;

GENETIC HETEROGENEITY; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PHENOTYPE; SINGLE-CELL ANALYSIS;

EID: 85007049088     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17122142     Document Type: Review

References (118)

1. Michor, F., Polyak, K. The origins and implications of intratumor heterogeneity. Cancer Prev. Res. (Phila.) 2010, 3, 1361-1364. [CrossRef] [PubMed]
2. Visvader, J.E. Cells of origin in cancer. Nature 2011, 469, 314-322. [CrossRef] [PubMed]
3. Fisher, R., Pusztai, L., Swanton, C. Cancer heterogeneity: Implications for targeted therapeutics. Br. J. Cancer 2013, 108, 479-485. [CrossRef] [PubMed]
4. Alix-Panabieres, C., Pantel, K. The circulating tumor cells: Liquid biopsy of cancer. Klin. Lab. Diagn. 2014, 4, 60-64. [CrossRef] [PubMed]
5. Gabriel, M.T., Calleja, L.R., Chalopin, A., Ory, B., Heymann, D. Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. Clin. Chem. 2016, 62, 571-581. [CrossRef] [PubMed]
6. Fidler, I.J., Hart, I.R. Biological diversity in metastatic neoplasms: Origins and implications. Science 1982, 217, 998-1003. [CrossRef] [PubMed]
7. Hayes, D.F., Paoletti, C. Circulating tumour cells: Insights into tumour heterogeneity. J. Intern. Med. 2013, 274, 137-143. [CrossRef] [PubMed]
8. Friedl, P., Alexander, S. Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 2011, 147, 992-1009. [CrossRef] [PubMed]
9. Andrechek, E.R., Nevins, J.R. Mouse models of cancers: Opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. J. Mol. Med. (Berl.) 2010, 88, 1095-1100. [CrossRef] [PubMed]
10. Somasundaram, R., Villanueva, J., Herlyn, M. Intratumoral heterogeneity as a therapy resistance mechanism: Role of melanoma subpopulations. Adv. Pharmacol. 2012, 65, 335-359. [PubMed]
11. Nassar, A., Radhakrishnan, A., Cabrero, I.A., Cotsonis, G.A., Cohen, C. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: A tissue microarray-based study. Appl. Immunohistochem. Mol. Morphol. 2010, 18, 433-441. [CrossRef] [PubMed]
12. Visvader, J.E., Lindeman, G.J. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8, 755-768. [CrossRef] [PubMed]
13. Nowell, P.C. The clonal evolution of tumor cell populations. Science 1976, 194, 23-28. [CrossRef] [PubMed]
14. Mazor, T., Pankov, A., Song, J.S., Costello, J.F. Intratumoral Heterogeneity of the Epigenome. Cancer Cell 2016, 29, 440-451. [CrossRef] [PubMed]
15. Portela, A., Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28, 1057-1068. [CrossRef] [PubMed]
16. Chekhun, V.F., Demash, D.V., Nalieskina, L.A. Evaluation of biological effects and possible mechanisms of action of static magnetic field. Fiziol. Zh. 2012, 58, 85-94.
17. Cassidy, J.W., Caldas, C., Bruna, A. Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts. Cancer Res. 2015, 75, 2963-2968. [CrossRef] [PubMed]
18. Tlsty, T.D., Coussens, L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 2006, 1, 119-150. [CrossRef] [PubMed]
19. Turner, N.C., Reis-Filho, J.S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012, 13, e178-e185. [CrossRef]
20. Wu, J.M., Fackler, M.J., Halushka, M.K., Molavi, D.W., Taylor, M.E., Teo, W.W., Griffin, C., Fetting, J., Davidson, N.E., de Marzo, A.M., et al. Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin. Cancer Res. 2008, 14, 1938-1946. [CrossRef] [PubMed]
21. Wicha, M.S. Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res. 2008, 10, 105. [CrossRef] [PubMed]
22. Guidi, A.J., Berry, D.A., Broadwater, G., Perloff, M., Norton, L., Barcos, M.P., Hayes, D.F. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J. Natl. Cancer Inst. 2000, 92, 486-492. [CrossRef] [PubMed]
23. Greaves, M., Maley, C.C. Clonal evolution in cancer. Nature 2012, 481, 306-313. [CrossRef] [PubMed]
24. Gundem, G., van Loo, P., Kremeyer, B., Alexandrov, L.B., Tubio, J.M., Papaemmanuil, E., Brewer, D.S., Kallio, H.M., Hognas, G., Annala, M., et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015, 520, 353-357. [CrossRef] [PubMed]
25. Hong, M.K., Macintyre, G., Wedge, D.C., van Loo, P., Patel, K., Lunke, S., Alexandrov, L.B., Sloggett, C., Cmero, M., Marass, F., et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 2015, 6, 6605. [CrossRef] [PubMed]
26. Negrini, S., Gorgoulis, V.G., Halazonetis, T.D. Genomic instability—An evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 2010, 11, 220-228. [CrossRef] [PubMed]
27. Hanahan, D., Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 14, 646-674. [CrossRef] [PubMed]
28. Dakubo, G.D., Jakupciak, J.P., Birch-Machin, M.A., Parr, R.L. Clinical implications and utility of field cancerization. Cancer Cell Int. 2007, 7, 2. [CrossRef] [PubMed]
29. Lichtenstein, A.V. Clonal heterogeneity of tumor may be due to continuous influx of newly transformed cells. Cancer Biol. Ther. 2006, 5, 1263-1264. [CrossRef] [PubMed]
30. Marusyk, A., Almendro, V., Polyak, K. Intra-tumour heterogeneity: A looking glass for cancer? Nat. Rev. Cancer 2012, 12, 323-334. [CrossRef] [PubMed]
31. Assie, G., Letouze, E., Fassnacht, M., Jouinot, A., Luscap, W., Barreau, O., Barreau, O., Omeiri, H., Rodriguez, S., Perlemoine, K., et al. Integrated genomic characterization of adrenocortical carcinoma. Nat. Genet. 2014, 46, 607-612. [CrossRef] [PubMed]
32. Wilting, R.H., Dannenberg, J.H. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist. Updates 2012, 15, 21-38. [CrossRef] [PubMed]
33. Eriksen, A.H., Andersen, R.F., Nielsen, B.S., Sorensen, F.B., Appelt, A.L., Jakobsen, A., Hansen, T.F. Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer. PLoS ONE 2016, 11, e0156919. [CrossRef] [PubMed]
34. Berdasco, M., Esteller, M. Aberrant epigenetic landscape in cancer: How cellular identity goes awry. Dev. Cell 2010, 19, 698-711. [CrossRef] [PubMed]
35. Place, R.F., Li, L.C., Pookot, D., Noonan, E.J., Dahiya, R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. USA 2008, 105, 1608-1613. [CrossRef] [PubMed]
36. Vermaat, J.S., Nijman, I.J., Koudijs, M.J., Gerritse, F.L., Scherer, S.J., Mokry, M., Roessingh, W.M., Lansu, N., de Bruijn, E., van Hillegersberg, R., et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: Implications for selection of patients for targeted treatment. Clin. Cancer Res. 2012, 18, 688-699. [CrossRef] [PubMed]
37. Vakiani, E., Janakiraman, M., Shen, R., Sinha, R., Zeng, Z., Shia, J., Cercek, A., Kemeny, N., D’Angelica, M., Viale, A., et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J. Clin. Oncol. 2012, 30, 2956-2962. [CrossRef] [PubMed]
38. Siyar Ekinci, A., Demirci, U., Cakmak Oksuzoglu, B., Ozturk, A., Esbah, O., Ozatli, T., Celik, B., Budakoglu, B., Turker, I., Bal, O., et al. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. J. BUON 2015, 20, 128-135. [PubMed]
39. Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., de Giorgi, V., Massi, D., Fonsatti, E., Staibano, S., Nappi, O., et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol. 2012, 30, 2522-2529. [CrossRef] [PubMed]
40. Mao, C., Wu, X.Y., Yang, Z.Y., Threapleton, D.E., Yuan, J.Q., Yu, Y.Y., Tang, J.L. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci. Rep. 2015, 5, 8065. [CrossRef] [PubMed]
41. Cejas, P., Lopez-Gomez, M., Aguayo, C., Madero, R., Moreno-Rubio, J., de Castro Carpeno, J., Belda-Iniesta, C., Barriuso, J., Moreno Garcia, V., Diaz, E., et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: Implications for cancer therapy. Curr. Cancer Drug Targets 2012, 12, 124-131. [CrossRef] [PubMed]
42. Chen, Z.Y., Zhong, W.Z., Zhang, X.C., Su, J., Yang, X.N., Chen, Z.H., Yang, J.J., Zhou, Q., Yan, H.H., An, S.J., et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012, 17, 978-985. [CrossRef] [PubMed]
43. Steeg, P.S. Tumor metastasis: Mechanistic insights and clinical challenges. Nat. Med. 2006, 12, 895-904. [CrossRef] [PubMed]
44. Heitzer, E., Auer, M., Gasch, C., Pichler, M., Ulz, P., Hoffmann, E.M., Lax, S., Waldispuehl-Geigl, J., Mauermann, O., Lackner, C., et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013, 73, 2965-2975. [CrossRef] [PubMed]
45. Mostert, B., Jiang, Y., Sieuwerts, A.M., Wang, H., Bolt-de Vries, J., Biermann, K., Kraan, J., Lalmahomed, Z., van Galen, A., de Weerd, V., et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int. J. Cancer 2013, 133, 130-141. [CrossRef] [PubMed]
46. Mohamed Suhaimi, N.A., Foong, Y.M., Lee, D.Y., Phyo, W.M., Cima, I., Lee, E.X., Goh, W.L., Lim, W.Y., Chia, K.S., Kong, S.L., et al. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol. Oncol. 2015, 9, 850-860. [CrossRef] [PubMed]
47. Solakoglu, O., Maierhofer, C., Lahr, G., Breit, E., Scheunemann, P., Heumos, I., Pichlmeier, U., Schlimok, G., Oberneder, R., Kollermann, M.W., et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc. Natl. Acad. Sci. USA 2002, 99, 2246-2251. [CrossRef] [PubMed]
48. Kraus, J., Pantel, K., Pinkel, D., Albertson, D.G., Speicher, M.R. High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer 2003, 36, 159-166. [CrossRef] [PubMed]
49. Pailler, E., Auger, N., Lindsay, C.R., Vielh, P., Islas-Morris-Hernandez, A., Borget, I., Ngo-Camus, M., Planchard, D., Soria, J.C., Besse, B., et al. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. Ann. Oncol. 2015, 26, 1408-1415. [CrossRef] [PubMed]
50. Middleton, G., Crack, L.R., Popat, S., Swanton, C., Hollingsworth, S.J., Buller, R., Walker, I., Carr, T.H., Wherton, D., Billingham, L.J., et al. The National Lung Matrix Trial: Translating the biology of stratification in advanced non-small-cell lung cancer. Ann. Oncol. 2015, 26, 2464-2469. [CrossRef] [PubMed]
51. Jamal-Hanjani, M., Hackshaw, A., Ngai, Y., Shaw, J., Dive, C., Quezada, S., Middleton, G., de Bruin, E., Le Quesne, J., Shafi, S., et al. Tracking genomic cancer evolution for precision medicine: The lung TRACERx study. PLoS Biol. 2014, 12, e1001906. [CrossRef] [PubMed]
52. Joosse, S.A., Gorges, T.M., Pantel, K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol. Med. 2015, 7, 1-11. [CrossRef] [PubMed]
53. Au, S.H., Storey, B.D., Moore, J.C., Tang, Q., Chen, Y.L., Javaid, S., Sarioglu, A.F., Sullivan, R., Madden, M.W., O’Keefe, R., et al. Clusters of circulating tumor cells traverse capillary-sized vessels. Proc. Natl. Acad. Sci. USA 2016, 113, 4947-4952. [CrossRef] [PubMed]
54. Place, A.E., Jin Huh, S., Polyak, K. The microenvironment in breast cancer progression: Biology and implications for treatment. Breast Cancer Res. 2011, 13, 227. [CrossRef] [PubMed]
55. Alix-Panabieres, C., Pantel, K. Circulating tumor cells: Liquid biopsy of cancer. Clin. Chem. 2013, 59, 110-118. [CrossRef] [PubMed]
56. Gasch, C., Pantel, K., Riethdorf, S. Whole Genome Amplification in Genomic Analysis of Single Circulating Tumor Cells. Methods Mol. Biol. 2015, 1347, 221-232. [PubMed]
57. Toss, A., Mu, Z., Fernandez, S., Cristofanilli, M. CTC enumeration and characterization: Moving toward personalized medicine. Ann. Transl. Med. 2014, 2, 108. [PubMed]
58. Fabbri, F., Carloni, S., Zoli, W., Ulivi, P., Gallerani, G., Fici, P., Chiadini, E., Passardi, A., Frassineti, G.L., Ragazzini, A., et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett. 2013, 335, 225-231. [CrossRef] [PubMed]
59. Ni, X., Zhuo, M., Su, Z., Duan, J., Gao, Y., Wang, Z., Zong, C., Bai, H., Chapman, A.R., Zhao, J., et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc. Natl. Acad. Sci. USA 2013, 110, 21083-21088. [CrossRef] [PubMed]
60. Fernandez, S.V., Bingham, C., Fittipaldi, P., Austin, L., Palazzo, J., Palmer, G., Alpaugh, K., Cristofanilli, M. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res. 2014, 16, 445. [CrossRef] [PubMed]
61. Pestrin, M., Salvianti, F., Galardi, F., de Luca, F., Turner, N., Malorni, L., Pazzagli, M., di Leo, A., Pinzani, P. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol. Oncol. 2015, 9, 749-757. [CrossRef] [PubMed]
62. Sakaizawa, K., Goto, Y., Kiniwa, Y., Uchiyama, A., Harada, K., Shimada, S., Saida, T., Ferrone, S., Takata, M., Uhara, H., et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br. J. Cancer 2012, 106, 939-946. [CrossRef] [PubMed]
63. Nakazawa, M., Lu, C., Chen, Y., Paller, C.J., Carducci, M.A., Eisenberger, M.A., Luo, J., Antonarakis, E.S. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann. Oncol. 2015, 26, 1859-1865. [CrossRef] [PubMed]
64. Kobayashi, S., Canepa, H.M., Bailey, A.S., Nakayama, S., Yamaguchi, N., Goldstein, M.A., Huberman, M.S., Costa, D.B. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J. Thorac. Oncol. 2013, 8, 45-51. [CrossRef] [PubMed]
65. Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M.W., Donaldson, M.C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014, 345, 216-220. [CrossRef] [PubMed]
66. Markou, A., Farkona, S., Schiza, C., Efstathiou, T., Kounelis, S., Malamos, N., Georgoulias, V., Lianidou, E. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Clin. Cancer Res. 2014, 20, 5823-5834. [CrossRef] [PubMed]
67. Kovac, M., Blattmann, C., Ribi, S., Smida, J., Mueller, N.S., Engert, F., Castro-Giner, F., Weischenfeldt, J., Kovacova, M., Krieg, A., et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat. Commun. 2015, 6, 8940. [CrossRef] [PubMed]
68. Almendro, V., Marusyk, A., Polyak, K. Cellular heterogeneity and molecular evolution in cancer. Annu. Rev. Pathol. 2013, 8, 277-302. [CrossRef] [PubMed]
69. Itzkovitz, S., van Oudenaarden, A. Validating transcripts with probes and imaging technology. Nat. Methods 2011, 8 (Suppl. 4), S12-S19. [CrossRef] [PubMed]
70. Summersgill, B., Clark, J., Shipley, J. Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nat. Protoc. 2008, 3, 220-234. [CrossRef] [PubMed]
71. Park, S.Y., Gonen, M., Kim, H.J., Michor, F., Polyak, K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J. Clin. Investig. 2010, 120, 636-644. [CrossRef] [PubMed]
72. Fiegler, H., Geigl, J.B., Langer, S., Rigler, D., Porter, K., Unger, K., Carter, N.P., Speicher, M.R. High resolution array-CGH analysis of single cells. Nucleic Acids Res. 2007, 35, e15. [CrossRef] [PubMed]
73. Oostlander, A.E., Meijer, G.A., Ylstra, B. Microarray-based comparative genomic hybridization and its applications in human genetics. Clin. Genet. 2004, 66, 488-495. [CrossRef] [PubMed]
74. Wang, F., Flanagan, J., Su, N., Wang, L.C., Bui, S., Nielson, A., Wu, X., Vo, H.T., Ma, X.J., Luo, Y. RNAscope: A novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn. 2012, 14, 22-29. [CrossRef] [PubMed]
75. Lee, J.H., Daugharthy, E.R., Scheiman, J., Kalhor, R., Ferrante, T.C., Terry, R., Turczyk, B.M., Yang, J.L., Lee, H.S., Aach, J., et al. Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues. Nat. Protoc. 2015, 10, 442-458. [CrossRef] [PubMed]
76. Janiszewska, M., Liu, L., Almendro, V., Kuang, Y., Paweletz, C., Sakr, R.A., Weigelt, B., Hanker, A.B., Chandarlapaty, S., King, T.A., et al. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat. Genet. 2015, 47, 1212-1219. [CrossRef] [PubMed]
77. Setou, M., Shrivas, K., Sroyraya, M., Yang, H., Sugiura, Y., Moribe, J., Kondo, A., Tsutsumi, K., Kimura, Y., Kurabe, N., et al. Developments and applications of mass microscopy. Med. Mol. Morphol. 2010, 43, 1-5. [CrossRef] [PubMed]
78. Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472, 90-94. [CrossRef] [PubMed]
79. Navin, N., Hicks, J. Future medical applications of single-cell sequencing in cancer. Genome Med. 2011, 3, 31. [CrossRef] [PubMed]
80. Schoenborn, J.R., Nelson, P., Fang, M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin. Cancer Res. 2013, 19, 4058-4066. [CrossRef] [PubMed]
81. Thege, F.I., Lannin, T.B., Saha, T.N., Tsai, S., Kochman, M.L., Hollingsworth, M.A., Rhim, A.D., Kirby, B.J. Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: Characterization, optimization and downstream analysis. Lab Chip 2014, 14, 1775-1784. [CrossRef] [PubMed]
82. Gasch, C., Bauernhofer, T., Pichler, M., Langer-Freitag, S., Reeh, M., Seifert, A.M., Mauermann, O., Izbicki, J.R., Pantel, K., Riethdorf, S. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 2013, 59, 252-260. [CrossRef] [PubMed]
83. Emmert-Buck, M.R., Bonner, R.F., Smith, P.D., Chuaqui, R.F., Zhuang, Z., Goldstein, S.R., Weiss, R.A., Liotta, L.A. Laser capture microdissection. Science 1996, 274, 998-1001. [CrossRef] [PubMed]
84. Gawad, C., Koh, W., Quake, S.R. Single-cell genome sequencing: Current state of the science. Nat. Rev. Genet. 2016, 17, 175-188. [CrossRef] [PubMed]
85. Saliba, A.E., Westermann, A.J., Gorski, S.A., Vogel, J. Single-cell RNA-seq: Advances and future challenges. Nucleic Acids Res. 2014, 42, 8845-8860. [CrossRef] [PubMed]
86. Wen, L., Tang, F. Single-cell sequencing in stem cell biology. Genome Biol. 2016, 17, 71. [CrossRef] [PubMed]
87. Chen, K.H., Boettiger, A.N., Moffitt, J.R., Wang, S., Zhuang, X. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science 2015, 348, aaa6090. [CrossRef] [PubMed]
88. Rotem, A., Ram, O., Shoresh, N., Sperling, R.A., Goren, A., Weitz, D.A., Bernstein, B.E. Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. Nat. Biotechnol. 2015, 33, 1165-1172. [CrossRef] [PubMed]
89. Farlik, M., Sheffield, N.C., Nuzzo, A., Datlinger, P., Schonegger, A., Klughammer, J., Bock, C. Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics. Cell Rep. 2015, 10, 1386-1397. [CrossRef] [PubMed]
90. Doherty, R., Couldrey, C. Exploring genome wide bisulfite sequencing for DNA methylation analysis in livestock: A technical assessment. Front. Genet. 2014, 5, 126. [CrossRef] [PubMed]
91. Morris, T.J., Beck, S. Analysis pipelines and packages for Infinium HumanMethylation450 BeadChip (450k) data. Methods 2015, 72, 3-8. [CrossRef] [PubMed]
92. Wlodkowic, D., Darzynkiewicz, Z. Rise of the micromachines: Microfluidics and the future of cytometry. Methods Cell Biol. 2011, 102, 105-125. [PubMed]
93. Werner, M., Merenda, F., Piguet, J., Salathe, R.P., Vogel, H. Microfluidic array cytometer based on refractive optical tweezers for parallel trapping, imaging and sorting of individual cells. Lab Chip 2011, 11, 2432-2439. [CrossRef] [PubMed]
94. Sood, A., Miller, A.M., Brogi, E., Sui, Y., Armenia, J., McDonough, E., Santamaria-Pang, A., Carlin, S., Stamper, A., Campos, C., et al. Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight 2016, 1, 6. [CrossRef] [PubMed]
95. Xu, X., Hou, Y., Yin, X., Bao, L., Tang, A., Song, L., Li, F., Tsang, S., Wu, K., Wu, H., et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012, 148, 886-895. [CrossRef] [PubMed]
96. Shah, S.P., Morin, R.D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., Delaney, A., Gelmon, K., Guliany, R., Senz, J., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461, 809-813. [CrossRef] [PubMed]
97. Alix-Panabieres, C., Pantel, K. Technologies for detection of circulating tumor cells: Facts and vision. Lab Chip 2014, 14, 57-62. [CrossRef] [PubMed]
98. Gawad, C., Koh, W., Quake, S.R. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. Proc. Natl. Acad. Sci. USA 2014, 111, 17947-17952. [CrossRef] [PubMed]
99. Yeung, K.Y., Fraley, C., Murua, A., Raftery, A.E., Ruzzo, W.L. Model-based clustering and data transformations for gene expression data. Bioinformatics 2001, 17, 977-987. [CrossRef] [PubMed]
100. Navin, N.E. Cancer genomics: One cell at a time. Genome Biol. 2014, 15, 452. [CrossRef] [PubMed]
101. De Luca, F., Rotunno, G., Salvianti, F., Galardi, F., Pestrin, M., Gabellini, S., Simi, L., Mancini, I., Vannucchi, A.M., Pazzagli, M., et al. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget 2016, 7, 26107-26119. [PubMed]
102. Jiang, R., Lu, Y.T., Ho, H., Li, B., Chen, J.F., Lin, M., Li, F., Wu, K., Wu, H., Lichterman, J., et al. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. Oncotarget 2015, 6, 44781-44793. [PubMed]
103. Powell, A.A., Talasaz, A.H., Zhang, H., Coram, M.A., Reddy, A., Deng, G., Telli, M.L., Advani, R.H., Carlson, R.W., Mollick, J.A., et al. Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 2012, 7, e33788. [CrossRef] [PubMed]
104. Lang, J.E., Scott, J.H., Wolf, D.M., Novak, P., Punj, V., Magbanua, M.J., Zhu, W., Mineyev, N., Haqq, C.M., Crothers, J.R., et al. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res. Treat. 2015, 149, 121-131. [CrossRef] [PubMed]
105. Sun, J., Masterman-Smith, M.D., Graham, N.A., Jiao, J., Mottahedeh, J., Laks, D.R., Ohashi, M., DeJesus, J., Kamei, K., Lee, K.B., et al. A microfluidic platform for systems pathology: Multiparameter single-cell signaling measurements of clinical brain tumor specimens. Cancer Res. 2010, 70, 6128-6138. [CrossRef] [PubMed]
106. Kotecha, N., Flores, N.J., Irish, J.M., Simonds, E.F., Sakai, D.S., Archambeault, S., Diaz-Flores, E., Coram, M., Shannon, K.M., Nolan, G.P., et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008, 14, 335-343. [CrossRef] [PubMed]
107. Irish, J.M., Myklebust, J.H., Alizadeh, A.A., Houot, R., Sharman, J.P., Czerwinski, D.K., Nolan, G.P., Levy, R. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc. Natl. Acad. Sci. USA 2010, 107, 12747-12754. [CrossRef] [PubMed]
108. Palazzo, A.L., Evensen, E., Huang, Y.W., Cesano, A., Nolan, G.P., Fantl, W.J. Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. PLoS ONE 2011, 6, e24592. [CrossRef] [PubMed]
109. Bandura, D.R., Baranov, V.I., Ornatsky, O.I., Antonov, A., Kinach, R., Lou, X., Pavlov, S., Vorobiev, S., Dick, J.E., Tanner, S.D. Mass cytometry: Technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal. Chem. 2009, 81, 6813-6822. [CrossRef] [PubMed]
110. Alizadeh, A.A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., et al. Toward understanding and exploiting tumor heterogeneity. Nat. Med. 2015, 21, 846-853. [CrossRef] [PubMed]
111. Qiu, P., Simonds, E.F., Bendall, S.C., Gibbs, K.D., Jr., Bruggner, R.V., Linderman, M.D., Sachs, K., Nolan, G.P., Plevritis, S.K. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat. Biotechnol. 2011, 29, 886-891. [CrossRef] [PubMed]
112. Han, L., Qiu, P., Zeng, Z., Jorgensen, J.L., Mak, D.H., Burks, J.K., Schober, W., McQueen, T.J., Cortes, J., Tanner, S.D., et al. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytom. A 2015, 87, 346-356. [CrossRef] [PubMed]
113. Carpenter, E.L., Rader, J., Ruden, J., Rappaport, E.F., Hunter, K.N., Hallberg, P.L., Krytska, K., O’Dwyer, P.J., Mosse, Y.P. Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells. Front. Oncol. 2014, 4, 201. [CrossRef] [PubMed]
114. Polzer, B., Medoro, G., Pasch, S., Fontana, F., Zorzino, L., Pestka, A., Andergassen, U., Meier-Stiegen, F., Czyz, Z.T., Alberter, B., et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol. Med. 2014, 6, 1371-1386. [CrossRef] [PubMed]
115. Murlidhar, V., Ramnath, N., Nagrath, S., Reddy, R.M. Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection. Cancers (Basel) 2016, 8, 61. [CrossRef] [PubMed]
116. Martelotto, L.G., Ng, C.K., Piscuoglio, S., Weigelt, B., Reis-Filho, J.S. Breast cancer intra-tumor heterogeneity. Breast Cancer Res. 2014, 16, 210. [CrossRef] [PubMed]
117. Dey, S.S., Kester, L., Spanjaard, B., Bienko, M., van Oudenaarden, A. Integrated genome and transcriptome sequencing of the same cell. Nat. Biotechnol. 2015, 33, 285-289. [CrossRef] [PubMed]
118. Gerdes, M.J., Sood, A., Sevinsky, C., Pris, A.D., Zavodszky, M.I., Ginty, F. Emerging understanding of multiscale tumor heterogeneity. Front. Oncol. 2014, 4, 366. [CrossRef] [PubMed]